Accéder au contenu
Merck

Antinociceptive synergism of gabapentin and nortriptyline in mice with partial sciatic nerve ligation.

Pharmacology (2015-01-17)
Hugo F Miranda, Viviana Noriega, Ramiro Zepeda, Pilar Zanetta, Josefina Prieto-Rayo, Juan Carlos Prieto, Fernando Sierralta
RÉSUMÉ

Neuropathic pain results from nerve injury, and gabapentin, an antiepileptic drug, has been approved for the treatment of several types of neuropathic pain. On the other hand, nortriptyline, an antidepressant drug, has been suggested as an alternative treatment. In partial sciatic nerve ligation (PSNL) mice, the interaction of gabapentin with nortriptyline was evaluated by the hot plate assay using isobolographic analysis. Gabapentin (3-100 mg/kg, i.p.) or nortriptyline (1-30 mg/kg, i.p.) induced dose-dependent antinociception, with an ED50 of 11.60 ± 0.54 mg/kg for gabapentin and of 5.16 ± 0.21 mg/kg for nortriptyline. The potency of gabapentin and nortriptyline in PSNL mice at 7 and 14 days after ligation was significantly increased (p < 0.05). Coadministration of gabapentin with nortriptyline, at a 1:1 ratio of their ED50, had a synergistic effect, with an interaction index of 0.311 and 0.348 for these mice at 7 and 14 days, respectively. The data showed a synergy in antinociception at a gabapentin-to-nortriptyline ratio of 1:1 in PSNL mice. This finding suggests that this combination could provide a therapeutic alternative that can be used for neuropathic pain management.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Nortriptyline hydrochloride, ≥98% (HPLC), powder
USP
Nortriptyline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Nortriptyline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Nortriptyline for system suitability, European Pharmacopoeia (EP) Reference Standard